KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Assets: 2017-2025

Historic Current Assets for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $151.7 million.

  • Aquestive Therapeutics' Current Assets rose 57.06% to $151.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.7 million, marking a year-over-year increase of 57.06%. This contributed to the annual value of $88.2 million for FY2024, which is 115.35% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Current Assets stood at $151.7 million for Q3 2025, which was up 85.60% from $81.7 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Current Assets registered a high of $151.7 million during Q3 2025, and its lowest value of $38.1 million during Q3 2022.
  • Moreover, its 3-year median value for Current Assets was $88.2 million (2024), whereas its average is $81.1 million.
  • In the last 5 years, Aquestive Therapeutics' Current Assets dropped by 24.14% in 2022 and then soared by 161.41% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Current Assets (Quarterly) stood at $47.3 million in 2021, then declined by 15.60% to $39.9 million in 2022, then rose by 2.70% to $41.0 million in 2023, then spiked by 115.35% to $88.2 million in 2024, then skyrocketed by 57.06% to $151.7 million in 2025.
  • Its last three reported values are $151.7 million in Q3 2025, $81.7 million for Q2 2025, and $89.2 million during Q1 2025.